REALLY encouraging numbers for the week of 5/30. Most drugs I follow down 10-17% because it was a 4 day work week with memorial day so its normal for numbers to take a big hit BUT for week of 5/30, TRX 249 vs 204 for prior week, UP 22%. NRx 174 vs 143 prior week, up 22%. Encouraging.
Not too exciting. TRx 204 vs 218 week of 5/16. NRX 143 v 176 prior week. Keep in mind with any new release there are always some down weeks, as long as it doesn't become a trend
Bad news folks. I am, for the time being, "out of commission" in terms of script date. Trying to get it back but even if I do, not likely it will be today
rebecca, we all know you are that chubby "reporter" from Oklahoma who gets paid by Streetsweeper which has mob ties according to the United States Government. We all know your game. Good luck with your short, which isn't going very well for you. It's going to get worse for you. A lot worse.
..."A last minute switch by 3 panelists on the efficacy question ended the day with a bizarre twist, given that the panelists had earlier voted overwhelmingly in favor of device efficacy @12 & 18 months. Hopes remain high that VBLOCK should get FDA approval based on the benefit vs risk vote.. In our opinion, the fact that the FDA asked the panel as to what should be a "reasonable" consideration of weight loss (as well as the definition of what type of weight loss should be used) was in and of itself emblematic of how complex obesity is, and nailing down a rigid protocol remains problematic....Overall, it seemed to us that the FDA had a relatively benign outlook towards VBLOC therapy especially given the multi-factorial nature of the disease and the clinical effects seen with VBLOC. In our discussions with the company, management believes that the Lerner template for weighing devices based on risk-benefits would trump all other concerns, and the positive panel vote on that metric bodes well for approvability of the device. Outperform, Price Target $7.00
Good stuff from old_wisetrader from OSIR board
Ozark, don't shoot the messenger, someone very knowledgeable with the wound care business has asked me to provide you with some facts regarding your conversation on studies.
I’m not too sure about the Grafix ‘high quality trial’ that you mentioned. Yes, they had 90 some people, and it had purported good results. Frankly, they should have – the population in the study had wounds that most likely would have healed on their own. Anyone who has been around wound care knows about the Sheehan study from back in 2003 that basically proved the trajectory of wounds that heal on their own with conservative therapy vs. those which need advanced therapies. This study is the basis for reimbursement and treatments in wound care and has been so for a decade or more. This basically said that if a wound area is reduced by 12.5% or more in a week, 25% or more in 2 weeks, or 50% or more in 4 weeks, it will likely go on to heal without any advanced therapy interventions. Now to the Grafix study – they allowed DFU’s with wound area reduction up to 30% in ONE week to be in the study! These are the easy to heal wounds! The EpiFix studies excluded anyone who healed more than 20% in TWO weeks, so their wounds were harder to heal. Also Ozark – you mentioned the demographics in the first EpiFix study, but you failed to mention that they did a cross-over study with the control patients and they healed at 90+% in about 8 weeks, so your argument does not hold water. Plus the 40 patients in the 1 week vs. 2 week EpiFix study with a 90% healing rate.
@adamfeuerstein: $GALE CEO Mark Ahn has been fired by the company’s board of directors, a source close to the co. tells me. Public announcement tomorrow.
Anyone read his note today? He (and in my opinion his short friends) are getting more and more desperate. AS the situation at MDXG gets better and better he keeps writing more and more notes explaining why he is "neutral" and why the future is bleak for MDXG. he hades two new "problems" ahead for MDXG today, one is not knowing how the acquisition by Medtronic will affect the distribution agreement between the companies and the other he brings up is the competition ahead for MDXG with ALQA, a company projected to do $4 million in total revenue in 2014. Yes, ALQA poses a threat to MDXG according to Suraj. Just goes to show you that anyone can become an analyst. The standards must be extraordinarily low.
What kills candyass is that he knows Doc, old_wisetrader, me and the other long time longs here are accredited investors ( something candyass will never be since it requires a specific net worth) who were in on the pipe or around that time under a buck and it kills him that we are sitting on a 7 banger which will be a 15-20 banger some time in 2015 while he worries month to month how he will be able to pay his rent on his little apartment and make the car payment on his Ford Focus.
Ahhh, a walk down memory lane. Prior posts by cezasse9
cezasse9 • May 20, 2014 2:52 PM
Poor Pete - always in trouble with the authorities.
cezasse9 • May 20, 2014 3:30 PM
SEC, FDA, BBB, ugh - who's next....
cezasse9 • May 20, 2014 9:21 PM
Halloween Candy - I like the way you think. It's about the SEC and FDA coming down hard on a SMUG Petit. Play with FIRE and get BURNED.
cezasse9 • May 21, 2014 12:58 PM Flag
Candyman - thanks for the heads up on this PIG. I'm shorting away and I will cover after the SEC and FDA tag team Poor Old Pete.... hehehehehehe
(By the way stock was about $5.41 on this date. Having fun cezasse9?)
And, remember this classic when cesasse9 thought the term states evidence applied in a civil trial? LOL. What an idiot. You are just a wealth of brilliant predictions. No doubt you are a complete failure in life.
cezasse9 • May 23, 2014 3:52 PM
Candyman - great day to short - - - WINK, WINK. Poor old Pete - just wait till Arrowood turns state's evidence. Gonna hurt for the MDXG faithful that day for sure.
LOL. This is an old suit and nothing will come of it as I just explained on the MDXG board. FWIW, same thing with OSIR's suit. These are ambulance chasers looking for a payoff to go away.
Halloween Candy not having a good week on his short. Poor candyman, or should I say Mr. Garcia. Your little fund and its attempt to short the wrong stock will not end well for you.
Amniofix is what turns MDXG into a potential billion dollar company yes. The FDA decision upcoming has no relevance towards that end. It is a traders' issue not an investors' issue.
I'll chime in. Basing your feeling on what Adcom members are asking is dangerous. It's their job to ask tough questions. I am an attorney and can tell you that the same applies when in front of an appellate court or Supreme Court. I have seen cases where the judges/justices seemed to be asking piercing questions leading one to believe that side was doomed and vice versa and yet the court decided in favor of the party to whom it was grilling. That's their job.
*Recent Medicare reimbursement changes are benefitting MDXG
** MDXG has entered a US distribution agreement with Medtronic's spine business..expects sales to begin to ramp after MDT's June spine sales meeting when it intends to introduce the product to its sales force. We believe that sales to Medtronic are a source of potential upside to estimates.
*MDXG's gross margin is very high and we expect profitability to ramp quickly as revenue outpaces operating expenses. Current GM in the mid 80s and is among the highest in the med tech sector. We believe it can reach a 17% operating margin in 2016 with revenue of around $200M.
*Combined opportunity of $13 billion. Wound care, surgical and sports med $2.5B, tendinopathy and pain management $7.5B and surgical barrier and scar prevention market is $3 billion.
*Outlook- In our model, we have revenue growing at a 50% CAGR from 2013 through 2016, with wound care revenue growing by a 71% CAGR and surgical, sports medicine & OEM growing by a 13% CAGR. However, we believe our estimates are likely to prove conservative (particularly for wound care) and we see potential for MiMedx's revenue CAGR to significantly exceed our estimates.